Please use this identifier to cite or link to this item:
https://doi.org/10.1038/cddis.2017.158
Title: | Silencing NKG2D ligand-Targeting miRNAs enhances natural killer cell-mediated cytotoxicity in breast cancer | Authors: | Shen, J Pan, J Du, C Si, W Yao, M Xu, L Zheng, H Xu, M Chen, D Wang, S Fu, P Fan, W |
Keywords: | histone deacetylase inhibitor ligand MICA protein MICB protein microRNA microRNA 17 92 microRNA 20a microRNA 20b mitogen activated protein kinase natural killer cell receptor NKG2D ULBP1 protein ULBP2 protein ULBP3 protein unclassified drug histone deacetylase inhibitor KLRK1 protein, human microRNA MIRN20 microRNA, human natural killer cell lectin like receptor subfamily K RNA tumor protein 3' untranslated region animal experiment animal model antigen recognition Article BC cell line Bcap37 cell line binding site breast cancer breast tissue BT-474 cell line cancer patient cancer prognosis cancer staging cancer survival cancer tissue controlled study down regulation enzyme inhibition gene cluster gene silencing gene targeting HS 578T cell line human human tissue in vitro study in vivo study ligand binding male MAPK signaling MCF-7 cell line MDA-MB-231 cell line MDA-MB-468 cell line mouse natural killer cell mediated cytotoxicity nonhuman overall survival priority journal protein analysis protein expression protein function SK-BR-3 cell line tumor immunogenicity upregulation animal breast tumor drug effects female genetics immunology natural killer cell pathology Animals Breast Neoplasms Female Histone Deacetylase Inhibitors Humans Killer Cells, Natural Male MAP Kinase Signaling System MCF-7 Cells Mice MicroRNAs Neoplasm Proteins NK Cell Lectin-Like Receptor Subfamily K RNA, Neoplasm |
Issue Date: | 2017 | Publisher: | Nature Publishing Group | Citation: | Shen, J, Pan, J, Du, C, Si, W, Yao, M, Xu, L, Zheng, H, Xu, M, Chen, D, Wang, S, Fu, P, Fan, W (2017). Silencing NKG2D ligand-Targeting miRNAs enhances natural killer cell-mediated cytotoxicity in breast cancer. Cell Death and Disease 8 (4) : e2740. ScholarBank@NUS Repository. https://doi.org/10.1038/cddis.2017.158 | Rights: | Attribution 4.0 International | Abstract: | NKG2D is one of the major activating receptors of natural killer (NK) cells and binds to several ligands (NKG2DLs). NKG2DLs are expressed on malignant cells and sensitize them to early elimination by cytotoxic lymphocytes. We investigated the clinical importance of NKG2DLs and the mechanism of NKG2DL regulation in breast cancer (BC). Among the NKG2DLs MICA/B and ULBP1/2/3, the expression levels of MICA/B in BC tissues were inversely associated with the Tumor Node Metastasis stage.We first found that the high expression of MICB, but not MICA, was an independent prognostic factor for overall survival in patients with BC. Investigation into the mechanism revealed that a group of microRNAs (miRNAs) belonging to the miR-17-92 cluster, especially miR-20a, decreased the expression of ULBP2 and MICA/B. These miRNAs downregulated the expression of MICA/B by targeting the MICA/B 3'-untranslated region and downregulated ULBP2 by inhibiting the MAPK/ERK signaling pathway. Functional analysis showed that the silencing of NKG2DL-Targeting miRNAs in BC cells increased NK cell-mediated cytotoxicity in vitro and inhibited immune escape in vivo. In addition, histone deacetylase inhibitors (HDACis) increased NKG2DL expression in BC cells by inhibiting members of the miR-17-92 cluster. Thus, targeting miRNAs with antisense inhibitors or HDACis may represent a novel approach for increasing the immunogenicity of BC. © The Author(s) 2017. | Source Title: | Cell Death and Disease | URI: | https://scholarbank.nus.edu.sg/handle/10635/179756 | ISSN: | 2041-4889 | DOI: | 10.1038/cddis.2017.158 | Rights: | Attribution 4.0 International |
Appears in Collections: | Elements Staff Publications |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1038_cddis_2017_158.pdf | 4.09 MB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License